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Background: Enumeration of circulating tumor cells (CTC) from whole blood permits moni-
toring of patients with breast carcinoma. Analysis of apoptosis & Bcl-2 expression in CTC
might add additional prognostic and predictive information. We estimated the degree of
these markers in CTC from patients being treated for metastatic breast cancer.
Methods: Eighty-three evaluable patients initiating a new therapy for metastatic breast can-
cer were enrolled. Whole blood was collected at baseline, at one of three short term time
windows (24, 48, or 72 h) after initiating treatment, and at first follow-up (3e5 weeks).
CTC were isolated, enumerated, and expression of M30 and Bcl2 was determined using the
CellSearch System.
Results: At baseline, window, and 3e5 weeks post-treatment, 41/80 (51%), 40/80 (50%) and
21/75 (28%) patients had 5 CTC, respectively. At baseline, the proportion of CTC-apoptosis
(M30) was inversely correlated with CTC number, and modestly inversely correlated with
CTC-Bcl-2. As expected, higher CTC levels at baseline or first follow-up were associated
with worse prognosis. Surprisingly, in patients with elevated CTC, higher levels of CTC-
apoptosis were associated with worse prognosis, while higher CTC-Bcl-2 levels corre-
lated with better outcomes.
Conclusions: CTC apoptosis and expression of Bcl-2 can be analytically determined in pa-
tients with metastatic breast cancer and may have biological and clinical implications.ls; FISH, Fluorescent in situ hybridization; PD, progressive disease; PFS, progression free sur-
is clinical trial have been reported at annual meetings (San Antonio Breast Cancer Sympo-
Oncology 2008).
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Published by Elsevier B.V. All rights reserved.1. Introduction 2.1. Study design and objectivesRecent technological advances have provided the means to
monitor circulating tumor cells (CTC) isolated from whole
blood from patients with epithelial malignancies (Hayes and
Smerage, 2008). CTC have been detected with a commercially
available, automated rare cell detection system (CellSearch
System; Veridex, LLC. Raritan NJ) in approximately 30e50%
of patients with metastatic colon, prostate and/or breast can-
cer (Cohen et al., 2009; Cristofanilli et al., 2004; de Bono et al.,
2008). In each disease, elevated CTC levels at baseline are
associated with shorter progression free and overall survival.
In metastatic breast cancer, persistently elevated CTC levels
(5 CTC/7.5 ml whole blood) after one cycle of treatment are
associated with a poor prognosis (Cristofanilli et al., 2004),
while a reduction in CTC levels indicates improved prognosis.
Furthermore, elevation of CTC levels at any time during
follow-up predicts a high risk of subsequent progression.
Furthermore, change in CTC levels is a more accurate indica-
tor of prognosis than independent review of radiographic ev-
idence of response (Budd et al., 2006; Hayes et al., 2006).
Not all patients with detectable CTC have a poor prognosis,
suggesting that further characterization of CTCmight provide
even more specific information regarding their biologic, and
clinical, significance (Cristofanilli et al., 2004). In addition, se-
rial characterization of CTCmight reflect themolecular evolu-
tion of cancer throughout its progression and thus represent a
“real-time,” non-invasive “virtual” biopsy. Thus, characteriza-
tion of clinically important biomarkers expressed by CTC is of
biological and clinical interest (Fehm et al., 2010; Hayes et al.,
2002; Meng et al., 2004b, 2006; Riethdorf et al., 2010).
Apoptosis (programmed cell death) within a tumor, before
or as a function of therapy, might predict benefit from thera-
peutic agents (Russo et al., 2006). In this regard, early
apoptosis can be detected via the monoclonal antibody
(M30) directed against a neo-epitope of cytokeratin 18 dis-
closed by caspase cleavage (Leers et al., 1999; Rossi et al.,
2010). In a complementary fashion, the analysis of the anti-
apoptotic B-cell lymphoma protein 2 (Bcl-2) might also predict
response to selected endocrine and chemotherapies (Callagy
et al., 2008).
In this pilot clinical study, we investigated whether CTC
apoptosis and Bcl-2 status could be determined at baseline,
within 24e72 h, and at first follow-up (w3e5 weeks) after
initiation of a new therapy in patients with metastatic breast
cancer.2. Methods
We report this study according to the REMARK guidelines (see
Figure 1 for REMARK diagram) (McShane et al., 2005).This was a prospective double-blind multi-center pilot study
approved by the University of Michigan and Cleveland Clinic
Institutional Review Boards. The primary objective of this
study was to determine the feasibility of detecting apoptosis
and Bcl-2 expression in CTC at various time intervals (base-
line, 24 h, 48 h, 72 h, and 3e4 weeks) in metastatic breast can-
cer patients starting a new endocrine or chemotherapy
(taxane or non-taxane-based). Secondary objectives were
designed to investigate the hypotheses that positive M30/
apoptosis CTC staining correlated with positive clinical out-
comes while positive Bcl-2 CTC staining was associated with
negative outcomes. We also proposed to correlate Bcl-2 and
M30 expression in CTCswith expression in tumor biopsy spec-
imens, which will be reported in a separate manuscript.2.2. Patient selection
All patients provided written informed consent prior to entry.
Eligibility was limited to patients with progressive metastatic
breast cancer and an ECOG status of 0e2 starting a new ther-
apeutic regimen.
We designed this trial to address several hypotheses: 1)
that apoptosis and Bcl-2 could be successfully determined
on CTC collected from patients with metastatic breast cancer;
2) that CTC levels, and apoptotic states, would change rapidly
within the first 24e72 h after initiation of therapy; 3) that these
early changes would differ according to systemic treatment
type (endocrine therapy, taxane-based or non-taxane-based
chemotherapy); and 4) that either at baseline or at early
follow-up windows these markers might have different pre-
dictive roles regarding outcomes, in patients treated with
different types of systemic therapies.
Accordingly, patients were assigned to a treatment cohort
depending on their independently prescribed therapeutic
regimen i.e., endocrine therapy (of any type), taxane-based
or non-taxane-based chemotherapeutic regimen. Endocrine
therapies included tamoxifen, fulvestrant, megestrol acetate,
or an aromatase inhibitor (anastrozole, exemestane, letro-
zole). Non-taxane chemotherapies included capecitabine, car-
boplatin, cyclophosphamide, doxorubicin, etoposide, 5-FU,
gemcitabine, ixabepilone, oxaliplatin, or vinorelbine, given
as single agents or in combination. Taxane-based regimens
included either paclitaxel, nanoalbumin bound-paclitaxel, or
docetaxel, alone or with other agents.
Our preclinical studies suggested that in vitro taxane-
induced apoptosis of cultured human breast cancer cell lines
occurs quite early (12e24 h) (data not shown). Therefore, we
addressed whether we could identify a rapid increase in
CTC-M30 (indicating apoptosis) after initiation of therapy. Pa-
tients elected to return for CTC testingwithin 24 h, 24e48 h, or
Figure 1 e REMARK diagram of patient flow in the clinical study.
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tion of the first dose of the new regimen. Patient entry into
each of these cohorts was based on their clinical situation
and their preference and was not randomly assigned. When
a specific window cohort was filled, accrual into that cohort
stopped. Patients were then encouraged to select one of the
remaining time windows available. Patient flow on the study
is illustrated in Figure 1.
Original protocol-planned accrual called for 9 patients with
elevated CTC (5 CTC/7.5 ml whole blood) in each time/win-
dow cohort. Previous studies (Budd et al., 2006; Cristofanilli
et al., 2004; Hayes et al., 2006) suggested that approximately
50% of patients in each cohort should have elevated CTC.
Thus, we estimated that a minimum of 18 patients would be
needed for each of nine treatment/window cohorts (total
plannedaccrual¼ 162patients).However, enrollmentwas sus-
pendedat n¼ 86 due to slower than expectedaccrual (Figure 1).
2.3. Patient staging and follow-up
Prior to starting a new systemic treatment, all patients had CT
and/or MRI scans of the chest and abdomen and a whole body
scintigraphic bone scan. Follow-up clinical evaluation was
performed at day 1 of each subsequent cycle for at least three
cycles. Cycle length was determined by the treating physician
according to the type of treatment the patient received (endo-
crine therapy was generally considered a 4 week cycle, and
chemotherapy was administered on either three or four
week cycles), which was most commonly 3e4 weeks long. Cli-
nicians were blinded to CTC results and to the independentassessment of radiographs, and all decisions regarding pa-
tient care were made using standard clinical and radiographic
evaluation performed at the clinical sites.
2.4. Blood draw and processing
Blood collections were scheduled at baseline, window
(24e72 h after the induction of therapy) and first follow-up
(w3e5 weeks) time periods for enumeration of CTC.
2.5. CTC enumeration and characterization
At each time point, approximately 30 mL of whole blood were
collected by drawing approximately 8 mL specimens into
evacuated 10 mL blood draw tubes containing an anti-
coagulant and a cellular preservative (CellSave Preservative
Tubes, Veridex, LLC. Raritan NJ). Specimens were maintained
at room temperature, and processed within 96 h of collection.
Upon receipt in the laboratory, the blood was pooled and
divided into three aliquots of 7.5 mL. One aliquot was used
for CTC enumeration þ apoptosis (M30) expression
(“apoptosis aliquot”) one for CTC enumeration þ Bcl-2 expres-
sion (“Bcl-2 aliquot”), and one for CTC enumeration alone
(“enumeration aliquot”), in that order of importance when
an insufficient volume of blood was available for testing of
all three.
CTC enumeration was performed using the CellSearch
System, which has been described previously (Allard et al.,
2003, 2004; Cristofanilli et al., 2004). The CellSearch CXC Kit
(Veridex, LLC. Raritan NJ) was used for the enrichment and
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Epithelial kit by the replacement of Cytokeratin 8,18, 19 conju-
gated to phycoerythrin (PE) with a fluorescein (FITC) conju-
gate. This change enables the subsequent characterization
of user-definedmarkers that appear at a relatively low antigen
density (w50,000 antigens/cell). Apoptosis in the CTC was
evaluated using a monoclonal antibody M30 (Peviva, Stock-
holm, Sweden) (Hagg et al., 2002; Leers et al., 1999) and Bcl-2
by monoclonal antibody Clone BCL-2/100 (BD Pharmingen,
San Diego, USA). Both antibodies were conjugated to phycoer-
ythrin (PE).
Positive and background controls for the M30-PE marker
consisted of normal blood spiked with apoptotic MCF7 cells
(MCF-7 apo cells). After seven days in culture, permitting over-
growth, cells floating in the supernatant were harvested.
These cells were fixed in 0.3% paraformaldehyde and sub-
jected to flow cytometry to monitor time-dependent
increasing M30 and decreasing full-length cytokeratin expres-
sion, consistent with cleavage of full-length cytokeratin 18
and appearance of the M30 neoantigen (Carr, 2000; Rossi
et al., 2010). The results were compared to flow cytometry
for M30 and cytokeratin 18 analysis of the adherent cells in
the same culture. Cytoplasmic M30 expression that occurred
in cells that were observed to have a 50% decrease of cytoker-
atin 18 compared to non-apoptotic adherent cells was chosen
to signify truly apoptotic cells. Cytoplasmic M30 staining wasFigure 2 e Composite figures of CTC analysis by CellSearch System, illus
CTC within a single blood specimen drawn from a patient with metastatic b
positive, CD45 negative, nucleated cells, representing CTC. Check marks be
for M30 (Figure 2A) or Bcl-2 (Figure 2B). Smudged events in the unchecked
that are negative for the respective markers.observed in 50e70% of the cells produced in this process, and
this level of M30 expression was used as a comparator for
patient-derived CTC-M30 evaluation. Figure 2 illustrates CTC
captured from blood collected from a patient with metastatic
breast cancer that have been processed in the CellSearch
System for enumeration and M30 (Figure 2A) and Bcl-2
(Figure 2B) staining. Patient derived CTC-M30 evaluation was
considered bi-categorical: Positive or Negative.
To ensure that the fixative in the CellSearch vacutainer
tubes does not induce apoptosis, cultured MCF-7 cells were
harvested before confluence and spiked into either CellSave
tubes or into 10 ml vacutainer tubes containing EDTA, and
then processed immediately (time 0) or after 24, 48, 72, and
96 h at room temperature using the CellSearch system. The
positive control MCF-7 apo cells were similarly prepared and
processed.
For cells spiked into CellSave tubes, at time 0, 0.9% of the
wild-type MCF-7 cells were positive for M30, compared to
53.3% of the MCF-7 apo cells. At 24, 48, 72, and 96 h, 0.5%,
0.5%, 0.5%, and 0.9% of the wild type MCF-7 cells were positive
for M30, respectively, compared to 53.6%, 40.5%, 44%, 32.6%,
and 41.4%, respectively, for the MCF-7 apo cells. For cells
spiked into EDTA-containing tubes without fixative, 0.7%
and 53.3% of the wild-type and MCF-7 apo cells, respectively,
were positive for M-30 at time 0. These data confirm that Cell-
Save fixative does not induce apoptosis, and they support thetrating the appearance of M30 (A) and Bcl-2 (B) negative and positive
reast cancer. Check marks beside the composite represent cytokeratin
side the composite for M30 and Bcl-2 represent CTC that are positive
frames represent cytokeratin positive, CD45 negative, nucleated cells
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studies of CTC-M30.
Results from one or more aliquots at each of the different
time points were not evaluable for several reasons, such as
insufficient blood draw volume, shipping delays, technical fail-
ures and specimen irregularities. Anticipating such issues, it
was predetermined that if there was insufficient blood volume,
the enumeration alone aliquot was not evaluated, and priority
was given to the phenotype aliquots (CTC-M30, CTC-Bcl-2).
2.6. Statistical analysis
Descriptive statistics and/or frequency distributions were
calculated for demographic and baseline clinical characteris-
tics. Derivation of the threshold level (5 CTC per 7.5 mL of
blood) for treatment decisions was described previously
(Cristofanilli et al., 2004). Significance of trends in percentages
of apoptotic and/or Bcl-2 positive cells by various CTC group-
ings were tested using a non-parametric test for trend across
ordered groups. Median apoptosis and Bcl2 levels were
compared using a non-parametric two-sample test on the
equality of medians where the null hypothesis is that the k
sampleswere drawn frompopulationswith the samemedian.
The chi-squared statistic with a continuity correction was
determined. The p-values were not adjusted formultiple com-
parisons. Progression free survival (PFS) was defined as the in-
terval from the date the CTC sample was drawn to the date of
disease progression, death, or last follow-up, whichever
occurred first. Overall survival (OS) was determined from the
date the CTC sample was drawn to the date of death or the
date of last contact with the patient. Any CTC blood samples
drawn after the date of progressive disease (PD) were excluded
from the PFS analyzes. Separate KaplaneMeier survival plots
were generated based on CTC levels at baseline and follow-
up blood collections. Survival curves were compared using
log-rank testing. Cox proportional hazards regression was
used to determine univariate and multivariate hazards ratios
for PFS and OS.3. Results
3.1. Patient demographics and CTC levels at baseline
Eighty-six (86) patients were enrolled (16 at the Cleveland
Clinic and 70 at the University of Michigan) between May
2005 andMarch 2008 (Figure 1). Three patients were not evalu-
able: one was not eligible, one withdrew prior to blood draw,
and one had no follow-up information beyond baseline blood
draw. Table 1 provides demographic information for the 83
evaluable patients and shows the proportion of patients
with 5 CTC in each of the three different aliquots at each
time point (see Methods, Section 2.6: apoptosis aliquot, Bcl2
aliquot, enumeration aliquot). Because of various, anticipated
specimen loss (see Methods), CTCs were evaluable at baseline
in 66 (80%), 80 (96%), and 75 (90%) of the enumeration,
apoptosis, and Bcl-2 aliquots, respectively (Table 1).
Consistent with previous reports (Cristofanilli et al., 2004;
Liu et al., 2009), approximately 50% of patients withmetastatic
breast cancer beginning a new treatment had elevated CTC(5 CTC/7.5 mL of whole blood). As also previously reported
(Cristofanilli et al., 2004; Liu et al., 2009), no biological or clin-
ical subgroup was more or less likely to have elevated CTC at
baseline (Table 1).
3.2. CTC changes with treatment and correlation with
clinical outcome
Table 2 provides the number of evaluable samples at each of
the time points in all patients aswell in each of the three treat-
ment cohorts for the CTC enumeration (2A), apoptosis (2B)
and Bcl-2 (2C) aliquots separately. This table also shows the
proportion of evaluable samples with 5 CTC. The largest
number of patients had evaluable data from their apoptosis
aliquot (Table 2B), thus, the data from the apoptosis aliquot
was used for the comparisons described in this section. At
baseline, 46%, 55%, and 53% of patients in the endocrine, tax-
ane and non-taxane cohorts, respectively, had elevated CTC
levels ( p ¼ 0.88) (Table 2B). For all patients, 40 of 80 (50%) pa-
tients at the window time point had elevated CTC, which did
not significantly differ from baseline (Table 2B). Because there
were no significant differences between the proportion of pa-
tients with elevated CTC between the baseline and window
draws, no correlations between CTC levels at 24, 48, or 72 h
and progression free survival (PFS) were performed.
Only 21 of 73 (27%) (2 patients progressed prior to first
follow-up blood draw) had elevated CTC at first follow-up.
The observed reduction in the proportion of patients with
elevated CTC compared to baseline is consistent with prior
studies (Cristofanilli et al., 2004; Liu et al., 2009) and strongly
suggests response to systemic therapy (Table 2B). As expected
(Cristofanilli et al., 2004; Liu et al., 2009), PFS for those patients
with elevated CTC levels at first follow-up was significantly
shorter compared to patients who did not have elevated CTC
(median PFS for elevated vs. not: 3.4 months vs. 6.4 months,
p ¼ 0.0097) (Figure 3).
3.3. CTC apoptosis and Bcl-2 phenotype
CTC apoptotic and Bcl-2 status were determined at baseline,
window, and first follow-up (Table 3). Apoptosis was present
in an average of 42% (median ¼ 35%) of the CTCs in the 41
evaluable patients with 5 CTC at baseline compared to an
average of 49% (median ¼ 54%) and 41% (median ¼ 38%) of
CTC in the 40 and 21 patients with 5 CTC at window and first
follow-up, respectively (t-test p-values ¼ 0.2791 and 0.9071,
median p-values ¼ 0.318 and 0.788, respectively).
An average of 62% (median¼ 65%) of CTCswere positive for
Bcl-2 expression in the 36 evaluable patients with 5 CTC at
baseline compared to 64% (median ¼ 70%) and 63%
(median ¼ 77%) of CTC in the 33 and 21 patients with 5
CTC at window and first follow-up, respectively (t-test p-
values ¼ 0.7889 and 0.8575, median p-values ¼ 0.402 and
0.707, respectively). For all treatment cohorts combined, M30
positivity at baseline, an indication of apoptosis, was signifi-
cantly inversely associated with higher numbers of CTC
(Figure 4A; non-parametric test for trend across ordered
groups p < 0.001). Likewise, at window and first follow-up
evaluations, the percentage of cells positive for M30was lower
in patients with higher numbers of CTC, although these
Table 1 e Patient demographics and CTC levels.
Characteristic (N ¼ 83) N (%) N (%) with 5 CTC/7.5 mL at baseline
Enumeration
aliquot
Apoptosis
aliquot
Bcl-2
aliquot
(N ¼ 66) (N ¼ 80) (N ¼ 75)
All patients e 38 (58%) 41 (51%) 36 (48%)
Molecular phenotype of primary tumor
ERþ and/or PRþ and Her2 45 (54%) 22 (63%) 26 (59%) 21 (54%)
ER and PR and Her2 13 (16%) 6 (60%) 8 (62%) 8 (62%)
Her2þa 13 (16%) 5 (50%) 3 (27%) 4 (36%)
Unknown 12 (14%) 5 (45%) 4 (33%) 3 (25%)
Fisher’s exact p-value 0.734 0.136 0.208
Sites of metastasis
Single site 27 (33%) 9 (43%) 12 (46%) 10 (42%)
Two sites 33 (40%) 17 (68%) 19 (59%) 15 (52%)
Three sites 16 (19%) 10 (67%) 8 (50%) 9 (56%)
Four or more sites 7 (8%) 2 (40%) 2 (33%) 2 (33%)
Fisher’s exact p-value 0.269 0.577 0.708
Bone 62 (75%) 35 (70%) 39 (66%) 35 (64%)
Liver 30 (36%) 15 (60%) 14 (48%) 13 (45%)
Lung 26 (31%) 9 (41%) 9 (36%) 10 (42%)
Brain 8 (10%) 2 (33%) 3 (38%) 3 (38%)
Bone only 20 (24%) 9 (56%) 12 (63%) 10 (59%)
# of years between primary & metastatic diagnoses
2.0 Years 50 (60%) 21 (51%) 21 (45%) 19 (43%)
<¼1.9 Years 33 (40%) 17 (68%) 20 (61%) 17 (55%)
Fisher’s exact p-value 0.208 0.18 0.356
Treatment group
Hormonal therapy 28 (34%) 11 (52%) 13 (46%) 11 (44%)
Non-taxane therapy 34 (41%) 16 (62%) 17 (53%) 15 (50%)
Taxane therapy 21 (25%) 11 (58%) 11 (55%) 10 (50%)
Fisher’s exact p-value 0.78 0.882 0.916
Line of therapy
1st line 27 (33%) 11 (58%) 11 (46%) 9 (38%)
2nd line 24 (29%) 11 (58%) 13 (54%) 12 (57%)
3rd or higher line 32 (38%) 16 (57%) 17 (53%) 15 (50%)
Fisher’s exact p-value 1 0.883 0.398
a HER2þ ¼ immunohistochemistry 3þor FISH >2.0.
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data not shown). These data suggest that as a result of biolog-
ical forces (such as anoikis or treatment related phenomena),
CTC may commence apoptosis before, at the time of extrava-
sation, or during migration.
Bcl-2 was not associated with number of cells at baseline
(Figure 4B; non-parametric test for trend across ordered
groups p ¼ 0.415), window, or first follow-up evaluations
(Table 3 and data not shown). For patients with elevated
CTC at baseline (an average of 5 CTC in both the Bcl-2 and
apoptosis aliquots), there was a weak, inverse relationship be-
tween the proportions of CTC positive for Bcl-2 and apoptosis
(Figure 4C, Pearson’s correlation p ¼ 0.04).
Table 4 provides CTC-apoptosis and Bcl-2 status by treat-
ment cohorts at baseline, window, and first follow-up. Treat-
ment cohorts were too small to perform meaningful
outcomes analyzes of M30 or Bcl-2 staining, but the average
proportion of CTC that were apoptotic in patients with 5
CTC did not change significantly from baseline to window orfirst follow-up: 42%, 49%, and 41%, respectively. Likewise,
the average proportion of CTC that were Bcl-2 positive in pa-
tients with 5 CTC was unchanged at the three time-points
(62%, 64%, and 63%).
3.4. CTC-M30 (apoptosis) and Bcl-2 and clinical
outcomes
The primary objective of this studywas to investigate whether
CTC-Bcl-2 and CTC-M30 (apoptosis) could be analytically
determined and whether these appeared to differ or change
among the various treatment groups or time points. The study
was not intended, conducted, nor powered to identify
whether either of these two markers adds or complements
CTC enumeration as a prognostic factor. However, in an
exploratory secondary objective, we investigated the possibil-
ity of association between CTC-M30 and CTC-Bcl-2 expression
and outcomes. We compared PFS of patients with 0e4 CTC/
7.5 ml whole blood with those who had 5 CTC/7.5 ml whole
Table 2 e Patient cohorts and CTC levels.
Time point All patients Endocrine therapy Taxane therapy Non-taxane therapy
A. # (%) patients with 5 CTC enumeration aliquot (CTC)
Baseline 38/66 (58%) 11/21 (52%) 11/19 (58%) 16/26 (62%)
24 h 13/25 (52%) 2/7 (29%) 4/7 (57%) 7/11 (64%)
48 h 12/27 (44%) 3/6 (50%) 3/9 (33%) 6/12 (50%)
72 h 10/19 (53%) 5/8 (63%) 2/3 (67%) 3/8 (38%)
24, 48, or 72 h 35/71 (49%) 10/21 (48%) 9/19 (47%) 16/31 (52%)
1st follow-up 18/61 (30%) 3/16 (19%) 6/17 (35%) 9/28 (32%)
B. # (%) patients with 5 CTC apoptosis aliquot (M30)
Baseline 41/80 (51%) 13/28 (46%) 11/20 (55%) 17/32 (53%)
24 h 13/28 (46%) 3/10 (30%) 4/7 (57%) 6/11 (55%)
48 h 16/31 (52%) 4/9 (44%) 5/9 (56%) 7/13 (54%)
72 h 11/21 (52%) 5/8 (63%) 2/3 (67%) 4/10 (40%)
24, 48, or 72 h 40/80 (50%) 12/27 (44%) 11/19 (58%) 17/34 (50%)
1st follow-up 21/75 (28%) 9/26 (35%) 6/19 (32%) 6/30 (20%)
C. # (%) patients with 5 CTC Bcl-2 aliquot
Baseline 36/75 (48%) 11/25 (44%) 10/20 (50%) 15/30 (50%)
24 h 12/26 (46%) 2/10 (20%) 5/6 (83%) 5/10 (50%)
48 h 11/28 (39%) 4/9 (44%) 2/7 (29%) 5/12 (42%)
72 h 10/19 (53%) 5/8 (63%) 2/3 (67%) 3/8 (38%)
24, 48, or 72 h 33/73 (45%) 11/27 (41%) 9/16 (56%) 13/30 (43%)
1st follow-up 21/69 (30%) 9/25 (36%) 4/16 (25%) 8/28 (29%)
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(Figure 5B). We arbitrarily selected a cut-point of 50% of cells
stained positive for each marker to be considered “positive.”
Exploration of other cutoffs provided similar associations.
We originally hypothesized that positive CTC-M30 staining
would be associated with favorable outcomes, since it should
reflect non-viable CTC. In contrast, as illustrated in Figure 5A,Time from First Follow-Up Bloo
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dian PFS CTC-M30 positive vs. 0e4 CTC ¼ 4.1 vs. 5.8 months,
p ¼ 0.05) and trended to a worse prognosis than those with
negative CTC-M30 (<50% cells stained for M30; median PFS
CTC-M30 positive vs. CTC-M30 negative ¼ 4.1 vs. 6.6 months,d Draw (Months) - Apoptosis Aliquot
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Table 3 e CTC phenotypes for apoptosis and Bcl-2 according to time cohorts.
M30 CTC sample BCL2 CTC sample
# (%) of patients with 5 CTC % CTC M30þ # (%) of patients
with 5 CTC
% CTC Bcl-2þ
Average Median Average Median
Baseline
41/80 (51%) 42% 35% 36/75 (48%) 62% 65%
Post-treatment window (24, 48, or 72 h)
40/80 (50%) 49% 54% 33/73 (45%) 64% 70%
Compared to baseline: 0.2791* 0.318** Compared to baseline 0.7889* 0.402**
First follow-up (3e4 weeks)
21/75 (28%) 41% 38% 21/69 (30%) 63% 77%
Compared to baseline 0.9071* 0.788** Compared to baseline 0.8575* 0.707**
*Two-sample t-test with equal variance p-value.
**Non-parametric test for equality of medians p-value.
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apparently nor statistically different than for those with
0e4 CTC/7.5 ml whole blood (median PFS CTC-M30 negative
vs. 0e4 CTC ¼ 6.6 vs. 5.8 months, p ¼ 0.45). At first follow-
up, these observations were even more striking (Figure 5A).
Median PFS for patients with positive CTC-M30 was 0.9
months, compared to 6.4 and 4.1 months for patients with
0e4 CTC or negative CTC-M30 ( p ¼ 0.004 for comparison of
CTC-M30 positive vs. negative, 0.0001 for CTC-M30 positive
vs. 0e4 CTC, and 0.21 for CTC-M30 negative vs. 0e4 CTC).
We also hypothesized that CTC-Bcl-2 would be associated
with worse prognosis, since pre-clinical data suggest that
Bcl-2 prevents apoptosis and therefore should be associated
with both worse natural history and resistance to cytotoxic
therapies. Contrary to our pre-study supposition, CTC-Bcl-2
was associated with more favorable outcomes (Figure 5B). At
baseline, PFS for patients with low/negative CTC-Bcl-2 (<50%
cells positive for Bcl-2) was 3.2 months, compared to 5.4 and
6.1 months for patients with CTC-Bcl-2 positive or 0e4 CTC,
respectively ( p ¼ 0.02 for comparison of CTC-Bcl-2 negative
and 0e4 CTC; p ¼ 0.13 and 0.34 for comparison of CTC-Bcl-2
negative vs. positive and for CTC-Bcl-2 positive vs. 0e4 CTC,
respectively).
As with CTC-M30, the data at first follow-up were even
more dramatic (Figure 5B). PFS for thosewith residual elevated
CTC that were negative for Bcl-2 was 0.9 months, compared to
4.1 and 6.4 months for those with CTC-Bcl-2 positive or 0e4
CTC ( p ¼ 0.01 for CTC-Bcl-2 negative vs. CTC-Bcl-2 positive;
p < 0.0001 for CTC-Bcl-2 negative vs. 0e4 CTC; p ¼ 0.44 for
CTC-Bcl-2 positive vs. 0e4 CTC). Small numbers in this trial
prohibit further comparison of outcomes according to a com-
bination of CTC-M30 and CTC-Bcl-2. However, median overall
survival had not been reached and was >22 months for both
the fifteen patients with high CTC-M30 and low CTC-Bcl-2
and for the forty patients with 0e4 CTC (data not shown).4. Discussion
In this study, we report successful integration of two poten-
tially important cellular markers of breast cancer outcome,
apoptosis and Bcl-2, into an automated, fluorescently-basedimmunomagnetic system to detect CTC in patients with met-
astatic breast cancer. Our results demonstrate that these
markers can be monitored at baseline, within a few days of
initiation, and at first clinical follow-up after initiation of a
new systemic therapy.
More than 40% of CTC were positive for M30/apoptosis at
baseline. Bloodwas collected into vacutainer tubes containing
a fixative (CellSave) (Allard et al., 2003), but our pre-analytical
study demonstrates that this fixative does not induce
apoptosis. This observation suggests that many CTC undergo
apoptosis eitherwhile still in the tumor or as a function of sep-
aration from the parent cancer. Moreover, the relative percent
of apoptosis was inversely associated with CTC levels.
Several prior studies have demonstrated that CTC levels,
when enumerated with the CellSearch assay using strict
criteria to define cellular events, are associated with poor clin-
ical outcome in breast, colorectal, and prostate cancers (Budd
et al., 2006; Cohen et al., 2008; Cristofanilli et al., 2004, 2005; de
Bono et al., 2008; Hayes et al., 2006; Liu et al., 2009). Previously
reported studies have demonstrated that rigorous and careful
CTC evaluation, even if only for enumeration, is essential to
ensure the specificity for bad outcome that we and others
have demonstrated using the CellSearch platform (Attard
et al., 2011; Kraan et al., 2011; Ligthart et al., 2011). For
example, reports regarding novel solid state CTC capture
and separation techniques, such as with EpCAM-coated
microposts or non-immunologic filters, have suggested
intriguingly higher sensitivity rates in detecting CTC than
have been reported with CellSearch (Nagrath et al., 2007;
Zheng et al., 2007). These techniques provide an opportunity
to perform in situ cellular characterization for clinically impor-
tant molecular markers (Maheswaran et al., 2008). However,
clinical outcomes studies with these assays have not been re-
ported and the analytical and clinical utility of these assays
have not been confirmedwith any acceptable level of evidence
(Hayes et al., 1996; Simon et al., 2009; Teutsch et al., 2009). Our
data suggest that some proportion of these cells may not be
biologically viable. Indeed, Coumans et al. have demonstrated
increased sensitivity using CellSearch by broadening the
definition of a CTC when enumerating events, but the speci-
ficity for cancer vs. normal subjects decreased (Coumans
et al., 2010). If an image analysis algorithm was used to
Table 4 e CTC phenotypes for apoptosis and Bcl-2 according to treatme
Time point Average (median) % CTC pos
Apoptosis aliquot (M30)
All Endocrine
therapy
Taxane
therapy
Non-tax
thera
Baseline 42% (35%) 45% (39%) 48% (57%) 35% (26
24, 48, or 72 h 49% (54%) 59% (71%) 54% (67%) 39% (40
1st follow-up 41% (38%) 51% (50%) 27% (25%) 40% (34
A
B
C
Figure 4 e Association of CTC phenotypes and CTC levels at
baseline and with each other. A. Association of apoptosis, analyzed by
M30 expression, and number of CTC/7.5 ml whole blood in baseline
blood draw of patients with ‡1 CTC at baseline. B. Association of
Bcl-2 and number of CTC/7.5 ml whole blood in baseline blood draw
of patients with ‡1 CTC at baseline. C. Association of Bcl-2 and
apoptosis (analyzed by M30 expression) on CTC in baseline blood
draw of patients with an average between aliquot tubes of ‡5 CTC at
baseline.
M O L E C U L A R O N C O L O G Y 7 ( 2 0 1 3 ) 6 8 0e6 9 2688identify CTC, the more strict definitions of CTC provided the
best specificity and resulted in the largest difference in
survival.
We and others have reported successful phenotyping of
CTC for a number of molecular markers, using CellSearch
and other platforms and assay strategies. In addition to
EGFR mutations, these include HER2, urokinase plasminogen
activator receptor, estrogen and androgen receptor, the recep-
tor for insulin like growth factor, ERG and PTEN (Attard et al.,
2009; de Bono et al., 2007; Fehm et al., 2008; Hayes et al., 2002;
Ignatiadis et al., 2007; Kallergi et al., 2007; Maheswaran et al.,
2008; Meng et al., 2004b, 2006). Most if not all of these studies
have been, like ours, preliminary in nature and currently
incorporation of phenotypic data into CTC evaluation has
not gained widespread clinical application in breast or other
epithelial malignancies (Harris et al., 2007).
We chose to phenotype for apoptosis and Bcl-2 expression
because of the obvious association between bothmarkers and
cell death, and the reported association between Bcl-2 expres-
sion and breast cancer (Cory and Adams, 2002). In addition to
their presumed association with prognosis, we also hypothe-
size that Bcl-2 expression might be a marker for relative ther-
apeutic resistance, and that serial apoptosismonitoringmight
be provide insight into the relative sensitivity of resistance to
a therapeutic regime chosen for an individual patient.
A number of studies have addressed the potential clinical
validity of monitoring circulating M30 protein levels (techni-
cally, the epitope of M30 on soluble cytokeratin 18 fragments
in the circulation) in patients with a variety of epithelial ma-
lignancies, either before or after treatment (Ausch et al.,
2009; Cummings et al., 2008; Dean et al., 2011; Hou et al.,
2009; Koelink et al., 2009). More germane to the current study,
CTC-M30 has been studied in colon, renal cell, ovarian, and
breast cancer (Behbakht et al., 2011; Fehm et al., 2006; Rossi
et al., 2010, 2012). Our data are consistent with those of Rossi
et al., suggesting a very high rate of CTC-M30 before treatment
(Rossi et al., 2010, 2012).
Fehm et al. reported that the presence of M30-positive
apoptotic DTC correlate with favorable response to therapy
(Fehm et al., 2006). Our trial was not designed to address either
the prognostic, predictive, or monitoring utility of baseline or
changes in CTC-Bcl2 or M30 with sufficient power, and we are
unable to speculate whether we might have observed relative
benefit or not in patient treatment cohorts according to base-
line or serial CTC phenotypes. In exploratory analyzes, we
observed that CTC levels decreased from baseline to first
follow-up in approximately one-half of those who were
initially elevated, consistent with response. However, went and time cohorts.
itive for marker in patients with 5 CTC
Bcl-2 aliquot
ane
py
All Endocrine
therapy
Taxane
therapy
Non-taxane
therapy
%) 62% (65%) 68% (64%) 62% (67%) 57% (44%)
%) 64% (70%) 65% (69%) 69% (88%) 59% (55%)
%) 63% (77%) 59% (61%) 88% (92%) 57% (66%)
AB
Figure 5 e PFS according to CTC enumeration as determined at baseline and 1st follow-up (w3e5 weeks after the initiation of therapy). M30 and
Bcl-2 positivity was only considered in patients with ‡5 CTC. A cutoff of ‡50% CTC positive for apoptosis (5A) or Bcl-2 (5B) was used to
distinguish positive from negative for construction of the KaplaneMeier curves. A. PFS according to CTC-apoptosis (as determined by M30
staining). (solid line: CTC<5/7.5 ml whole blood; dotted line: ‡5 CTC/7.5 ml whole blood and M30 negative; dashed line: ‡5 CTC/7.5 ml
whole blood and M30 positive). B. PFS according to CTC-Bcl-2. (solid line: CTC<5/7.5 ml whole blood; dotted line: ‡5 CTC/7.5 ml whole
blood and Bcl-2 negative; dashed line: ‡5 CTC/7.5 ml whole blood and Bcl-2 positive).
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either CTC number or phenotype between baseline and win-
dow blood draws, regardless of type of therapy.
In contrast to our pre-study hypothesis, CTC-Bcl-2 positivity
was associated with superior PFS, resembling that for patientswithout elevated CTC. The association between worse PFS and
proportion of CTC that are positive for apoptosis or negative
for Bcl-2 is counter-intuitive, and may be due to chance alone
given thesmallnumbersandheterogeneityofpatientsenrolled.
Further, outcomes analyzes of this dataset are almost certainly
M O L E C U L A R O N C O L O G Y 7 ( 2 0 1 3 ) 6 8 0e6 9 2690confounded because of the manner in which patients were
selected to address the primary aim of this study: the technical
aspects of performingCTC-apoptosis andCTC-Bcl-2 atdifferent
time windows and in different treatment subgroups. For
example, although a recently published paper suggests Bcl-2 is
associated with worse prognosis, this marker has been found
topredict favorableoutcomes inpatientswithERpositivebreast
cancer who received adjuvant endocrine therapy (Albain et al.,
2010; Callagy et al., 2008; Dowsett et al., 2010; Paik et al., 2004).
Thus, we hypothesize that perhaps CTC-apoptosis and Bcl-2
mightplayadifferent role inendocrinerefractorypatientsstart-
ing chemotherapy than they do for those with endocrine
responsive disease. Since some of our patients had ER positive
diseasewhileotherswereERnegative, andsomereceivedendo-
crine therapywhile others received chemotherapy, the associa-
tion of CTC-Bcl-2 with outcomes in our study may be quite
mixed.
We did not have sufficient power to perform even explor-
atory analyzes of CTC-phenotype associations according to
intrinsic subtype or type of treatment. However, as an illustra-
tive case, we present a 59 year old patient with predominantly
skeletal, ER and PR positive and HER2 negative metastatic
invasive ductal carcinoma. Extraskeletal sites included a sin-
gle pulmonary nodule and a small pleural effusion. Her only
prior chemotherapy was adjuvant doxorubicin and cyclo-
phosphamide given 7 years prior to the metastatic recurrence
of her cancer, and she had only received letrozole and fulves-
trant for metastatic disease prior to enrollment. On trial she
initiated weekly paclitaxel. Baseline CTCs were remarkably
elevated at 21,000/7.5 mL of whole blood, and four weeks later
the level doubled to 43,000 CTC/7.5 mL of whole blood. She
died of progressive visceral disease approximately 2-1/2
months after the initiation of paclitaxel. It was notable that
98e100% of her CTCs at baseline and throughout her follow-
up were strongly positive for Bcl-2 and were essentially nega-
tive for apoptosis, withM30 staining of 1e3% at all time points.
Thus, even though the overall results enigmatically suggested
that positive Bcl-2 and negative M30were associated with bet-
ter outcomes, this patient provides a case in which these
markers were associated with resistance to chemotherapy
and rapid progression and death.
Therefore, the unexpected results may truly reflect cancer
biology. The role that apoptosis and its control by Bcl-2 play in
the natural history of breast cancer is poorly understood, and,
perhaps even more important, the differential sensitivity and
resistance to different forms of therapy are conflicting. Our
findings might relate to the curious association reported by
many authors between increased proliferation, balanced by
apoptosis, in primary breast cancers (Lipponen et al., 1994;
Liu et al., 2001; Vakkala et al., 1999). Indeed, Meng et al. re-
ported that one third of breast cancer patients who were
asymptomatic and free of any evidence of recurrence for
7e22 years after primary and adjuvant therapy had detectable
CTC, and they speculated that dormancy must be a balance of
cell death and replenishment (Meng et al., 2004a).
Regardless of the phenotype data, the results from this pi-
lot study re-confirm the prognostic significance of CTC at
baseline and first follow-up for patientswithmetastatic breast
cancer (Hayes and Smerage, 2008). It should be noted that we
used a revised CTC capture and characterization assay(CellSearch CXC kit) which, because of exchange of the fluo-
rophores, is slightly less sensitive than the commercially
available FDA-approved kit. It is possible that this technical
issue confounded the outcomes analysis. Nonetheless, as in
other studies using the classic CellSearch kit, in the current
study approximately 50% of patients with progressive meta-
static breast cancer had 5 CTC at baseline, decreasing to
approximately 30% after one cycle of therapy, and those
with residual CTC had a much worse prognosis. Thus, we do
not believe that this concern is a valid confounder of the out-
comes we observed relative to Bcl-2 and M30 expression.
The clinical utility of reductionofCTCatfirst follow-up is the
objective of an ongoing prospective randomized clinical trial
(HayesandSmerage, 2008).Wehadhypothesized thatwemight
detect either CTC level or CTC apoptosis changes even sooner
(24, 48 or 72 h windows) in metastatic breast cancer patients
starting a new systemic therapy. However, we were unable to
observe, in either hormonally or chemotherapy-treated pa-
tients, anymeaningful changes in these parameters frombase-
line to window time points. Likewise, we did not detect any
associations between CTC-apoptosis or CTC-Bcl-2 at window
and CTC at first follow-up, nor between CTC-phenotype atwin-
dow and risk of subsequent progression.5. Conclusions
We have demonstrated that CTC can be characterized for
apoptotic and Bcl-2 phenotypes, and that these results may
have clinical implications. Further studies are needed to
incorporate these assays into larger, more definitive trials as
well as standard clinical practice.Statement of conflicts of interest
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